in a Cell-Based Brain Cancer Model
April 10th, 2019, Vancouver, British Columbia:PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce further positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program (the “Peptide Program”), that is expected to enable the Company to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.
Through preliminary screening in a glioblastoma (aggressive brain cancer) cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein (the “Target Protein”) implicit in the progression of certain glioblastomas (see news release dated March 11, 2019).
After further screening of the lead peptides in an invasion assay model, PreveCeutical is pleased to announce that the peptides’ abilities to inhibit the activity of the Target Protein and the invasion potential by glioblastoma cell types has been confirmed. This is an important development given that "invasion" is a key driver of the aggressiveness, the poor prognosis and the rapid spread of glioblastoma.
Although this screening process is nearing completion, the Peptide Program is ongoing. This latest encouraging development has helped progress the Company towards assessing the efficacy of the lead peptides in more sophisticated neural oncosphere cell models of glioblastoma. The results from such additional screening will be helpful in determining further applications of research generated from the Peptide Program.
Recent PRVCF News
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM